Discoverers of hepatitis C virus win Nobel medicine prize

Honour given special resonance in year when world is gripped by coronavirus pandemic
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news

Related Links:

Kizzmekia Corbett joins TWiV to review her career and her work on respiratory syncytial virus, influenza virus, and coronaviruses and coronavirus vaccines, including her role in development and testing of a spike-encoding mRNA vaccine, and then we review the Nobel Prize for discovery of hepatitis C virus. Click arrow to playDownload TWiV 670 (76 MB .mp3, […]
Source: virology blog - Category: Virology Authors: Tags: This Week in Virology coronavirus COVID-19 influenza virus mRNA-1273 pandemic prefusion conformation respiratory syncytial virus SARS-CoV-2 spike vaccine viral viruses Source Type: blogs
(STOCKHOLM) — Americans Harvey J. Alter and Charles M. Rice and British-born scientist Michael Houghton won the Nobel Prize for medicine on Monday for their discovery of the hepatitis C virus, a major source of liver disease that affects millions worldwide. Announcing the prize in Stockholm, the Nobel Committee noted that the trio’s work identified a major source of blood-borne hepatitis that couldn’t be explained by the previously discovered hepatitis A and B viruses. Their work, dating back to the 1970s and 1980s, has helped saved millions of lives, the committee said. “Thanks to their discovery, ...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized News News Desk wire Source Type: news
Authors: Pokorska-Śpiewak M, Śpiewak M Abstract In recent years, significant progress in the antiviral treatment of chronic hepatitis C (CHC) has been made due to the development of interferon-free therapies. Three different highly effective, oral direct-acting antiviral (DAA) regimens have been approved for use in adolescents with CHC between the ages of 12-years-old and 17-years-old in Europe. According to the current recommendations, all treatment-naïve and treatment-experienced children with CHC virus infection should be considered for DAA therapy to prevent the possible progression of hepatitis C virus-...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
We report 10 candidates with optimal binding features to the active site of the protease for further consideration as potential drugs to treat patients infected with the emerging COVID-19 disease. PMID: 32773989 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research
Vincent visits Ohio State University (March 2020) and speaks with Shan-Lu, David, Amanda, Mark, Matt, Chris, and Qiuhong about their careers and their work on retroviruses, hepatitis C virus, coronaviruses, paramyxoviruses, and environmental viruses. Click arrow to playDownload TWiV 650 (63 MB .mp3, 105 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
Source: virology blog - Category: Virology Authors: Tags: This Week in Virology coronavirus COVID-19 hepatitis C virus HTLV pandemic plant viruses retrovirus SARS-CoV-2 viral viroids Source Type: blogs
CONCLUSION: These promising drugs could inhibit the replication of the virus; hence, we suggest the repurposing of these compounds for thetreatment of COVID-19. No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA. However, the assessment of these potential inhibitors as clinical drugs involves further in vivo tests for these drugs. PMID: 32748740 [PubMed - as supplied by publisher]
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Tags: Comb Chem High Throughput Screen Source Type: research
Abstract Following the advent of penicillin as first widely used antibiotic during World War II, viruses have steadily replaced bacteria as major agents of infections, particularly for microorganisms that can spread globally. Good examples are pandemics caused by HIV, hepatitis B, hepatitis C, and nowadays severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus of coronavirus disease (COVID)-19. PMID: 32628223 [PubMed - as supplied by publisher]
Source: AIDS Reviews - Category: Infectious Diseases Authors: Tags: AIDS Rev Source Type: research
Authors: Stefano ML, Kream RM, Stefano GB Abstract The emergence of the novel ß-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic of coronavirus disease 2019 (COVID-19). Clinical studies have documented that potentially severe neurological symptoms are associated with SARS-CoV-2 infection, thereby suggesting direct CNS penetration by the virus. Prior studies have demonstrated that the destructive neurological effects of rabies virus (RABV) infections are mediated by CNS transport of the virus tightly bound to the nicotinic acetylcholine receptor (nACh...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Abstract Acute lung injury (ALI) represents the most severe form of the viral infection sustained by coronavirus disease 2019 (COVID-19). Today, it is a pandemic infection, and even if several compounds are used as curative or supportive treatment, there is not a definitive treatment. In particular, antiviral treatment used for the treatment of several viral infections (eg, hepatitis C, HIV, Ebola, severe acute respiratory syndrome-coronavirus) are today used with a mild or moderate effect on the lung injury. In fact, ALI seems to be related to the inflammatory burst and release of proinflammatory mediators that i...
Source: The Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: J Clin Pharmacol Source Type: research
Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination is RDV's plausible mechanism of action. Here, we exp...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Editors ' Picks Source Type: research
More News: Coronavirus | COVID-19 | Hepatitis | Hepatitis C | Pandemics | Pharmaceuticals